Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2001 September;45(3) > The Quarterly Journal of Nuclear Medicine 2001 September;45(3):257-68

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

  PET IN ONCOLOGY
Guest Editor: I. Carrio


The Quarterly Journal of Nuclear Medicine 2001 September;45(3):257-68

lingua: Inglese

Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET)

Baum R. P., Przetak Ch.

From the Zen­tralk­linik Bad ­Berka Clinic of ­Nuclear Med­i­cine, ­Center for PET, Bad ­Berka Ger­many


FULL TEXT  


Posi­tron emis­sion tomog­raphy (PET) has the poten­tial to con­tribute sig­nif­i­cantly to treat­ment plan­ning and to the eval­u­a­tion of ­response to ­therapy in ­patients ­with ­cancer. For dis­ease recur­rence PET ­imaging pro­vides infor­ma­tion non-inva­sively. The ­final ­goal is to bio­log­i­cally char­ac­terize an indi­vidual ­patient’s ­tumor and to pre­dict the ­response to treat­ment at the ear­liest pos­sible ­time. ­Since the devel­op­ment of neo­ad­ju­vant chem­o­therapy, PET has ­been ­proved to be the ­most sen­si­tive and accu­rate ­imaging tech­nique for ­early ­therapy ­response eval­u­a­tion of ­breast ­tumors. Quan­ti­ta­tive and/or ­semi-quan­ti­ta­tive PET ­studies ­yield val­u­able infor­ma­tion in ­breast ­cancer ­regarding prog­nosis and ­response to chem­o­hor­mon­therapy in a ­timely ­fashion. In ­ovarian ­cancer, up to now ­only few ­studies ­have ­been per­formed ­applying PET tech­niques for the eval­u­a­tion of treat­ment ­response. ­These pre­lim­i­nary ­studies indi­cate ­that ­serial assess­ment of ­tumor metab­olism by FDG-PET ­early ­during effec­tive chem­o­therapy may pre­dict sub­se­quent ­response to ­such ­therapy. PET ­studies can be ­repeated ­without any ­side-­effects and ­with low radi­a­tion expo­sure and ­results can be ­directly cor­re­lated ­with clin­ical labor­a­tory ­data and his­tology. The ­role of PET in the con­text of ­patient man­age­ment and the cost-ef­fec­tive­ness of ­this ­approach ­needs fur­ther eval­u­a­tion. ­Therapy mon­i­toring by PET ­could ­help to opti­mize neo­ad­ju­vant ­therapy pro­to­cols and to ­avoid inef­fec­tive pre­op­er­a­tive ­therapy in non-­responders, but ­this has to be ­proven in a ­larger ­number of ­patients and in dif­ferent neo­ad­ju­vant set­tings ­such as chem­o­therapy, radi­a­tion ­therapy, ­hormone ­therapy or a com­bi­na­tion of ­these.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail